Literature DB >> 15644835

The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs.

Lewis B Holmes1, Brent A Coull, Jon Dorfman, Peter B Rosenberger.   

Abstract

OBJECTIVE: Children exposed during pregnancy to the anticonvulsant drugs phenytoin, phenobarbital, and carbamazepine as monotherapy and polytherapy have an increased frequency of midface and digit hypoplasia. Some children also have cognitive dysfunction. The hypothesis tested is that the anticonvulsant drug-exposed child with midface and digit hypoplasia is more likely to have cognitive dysfunction.
METHODS: Children exposed to anticonvulsant drugs (n = 80) were recruited for a follow-up evaluation, which included testing cognitive function and a physical examination for head size, height, and the presence of midface and digit hypoplasia. Microcephaly, midface and digit hypoplasia, and major malformations were correlated with full scale (FSI), performance (PIQ) and verbal (VIQ) intelligence.
RESULTS: The presence of the 3 anticonvulsant-exposed children with microcephaly had a deficit of 23.7 IQ points in FSI in comparison with the other children with a normal head size. Either midface or digit hypoplasia, after excluding the persons with microcephaly and with the Bonferroni correction, correlated significantly with deficits in VIQ (-12.7), PIQ (-10) and FSI (-12.8) IQ points ( P = .0061). There was no decrease in IQ in association with major malformations.
CONCLUSION: The presence of midface and digit hypoplasia in a child exposed to anticonvulsant drugs in pregnancy is an indication for a systematic developmental evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644835     DOI: 10.1016/j.jpeds.2004.08.048

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism.

Authors:  Rachel Stadelmaier; Hanah Nasri; Curtis K Deutsch; Margaret Bauman; Anne Hunt; Christopher J Stodgell; Jane Adams; Lewis B Holmes
Journal:  Birth Defects Res       Date:  2017-06-21       Impact factor: 2.344

2.  In utero valproate exposure and autism: long suspected, finally proven.

Authors:  Cynthia L Harden
Journal:  Epilepsy Curr       Date:  2013-11       Impact factor: 7.500

3.  Laser light scan analysis of the "anticonvulsant face".

Authors:  H Ivan Orup; Curtis K Deutsch; Lewis B Holmes
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-05-27

Review 4.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

Review 5.  Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero.

Authors:  Rebecca L Bromley; Gus A Baker; Kimford J Meador
Journal:  Curr Opin Neurol       Date:  2009-04       Impact factor: 5.710

Review 6.  Long-term consequences after exposure to antiepileptic drugs in utero.

Authors:  Lisa Forsberg; Katarina Wide
Journal:  Ther Adv Drug Saf       Date:  2011-10

Review 7.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

Review 8.  Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.

Authors:  Rebecca Bromley; Jennifer Weston; Naghme Adab; Janette Greenhalgh; Anna Sanniti; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30

Review 9.  Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges.

Authors:  Richard A Epstein; Katherine M Moore; William V Bobo
Journal:  Drug Healthc Patient Saf       Date:  2014-12-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.